Protara Therapeutics Inc. (NASDAQ: TARA) reported updated 12-month data from its Phase 2 ADVANCED-2 trial of TARA-002 in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE